06.04.2016 22:05:48

Novavax to Present at the 15th Annual Needham Healthcare Conference

GAITHERSBURG, Md., April 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference.

Conference details are as follows:

Date: Wednesday, April 13, 2016
Time: 8:40 a.m. U.S. Eastern Time
Location: Westin Grand Central hotel, New York City
Live webcast: http://wsw.com/webcast/needham76/nvax

The webcast and a replay of the presentation will also be accessible under the "Investors/Events" section of the Novavax website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

Contact: Novavax, Inc.

              Barclay A. Phillips
              SVP, Chief Financial Officer and Treasurer

              Andrea N. Flynn, Ph.D.
              Senior Manager, Investor Relations

              ir@novavax.com
              240-268-2000

              Russo Partners, LLC

              David Schull
              Todd Davenport, Ph.D.

              david.schull@russopartnersllc.com
              todd.davenport@russopartnersllc.com
              212-845-4271




This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#2000927

Nachrichten zu Novavax Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Novavax Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!